Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>
NASDAQ | GEMP (Common Stock)
06/22/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press Releases More
Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Pediatric NAFLD05/18/18
Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update05/08/18
Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer05/03/18
Investor Events More
There are currently no events scheduled.